

# PATRICK S. WESTON, MD/MBA

Kellogg School of Management • Board Certified: Internal Medicine & Cardiovascular Disease

Active Medical Licenses: FL | TX | AZ | IL

[Phone +1(727) 888-1978] | [Email Contact@kpmd.com] | [Linked in:www.linkedin.com/in/patricksweston]

Principal Investigator on 100+ industry-sponsored clinical trials across FL, TX, AZ, and IL. Cardiometabolic and hepatology specialist with deep Phase 2/3 trial expertise in MASH/NASH, MACE endpoints, GLP-1 receptor agonists, and metabolic dysfunction-associated steatotic liver disease (MASLD). MD/MBA (Kellogg) with 20+ years of PI experience and a publication record spanning cardiovascular outcomes, diabetes, and metabolic disease. Available as Expert Witness for Product Liability, Mass Tort/MDL, and white-collar pharmaceutical litigation.

## THERAPEUTIC AREAS OF EXPERTISE

**MASH / NASH / MASLD / Hepatic Fibrosis**      **MACE Endpoints & Cardiovascular Outcomes**  
**GLP-1 Receptor Agonists & Metabolic Disease**      **Cardiometabolic Syndrome & Type 2 Diabetes**  
**FDA Regulatory Compliance & IND/NDA Frameworks**      **Clinical Trial Design: Phase 1-3, RCT, Adaptive**  
**Heart Failure, Hypertension & Renal Outcomes**      **Product Liability & Mass Tort (MDL) Expert Witness**

## EXPERT WITNESS & MEDICAL-LEGAL SERVICES

### Prudent Healthcare Advisors      May 2018 – Present

Expert Witness: Product Liability | Mass Tort/MDL | White Collar Pharmaceutical Litigation

File review, standard-of-care analysis, clinical trial methodology & FDA regulatory compliance opinions

### Independent Medical-Legal Consultant      Feb 2011 – May 2018

Expert consulting in cardiovascular and metabolic pharmaceutical matters

## CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR

**100+ Industry-Sponsored Clinical Trials**      Phase 1 through Phase 3 | Multi-site, multi-national | FL, TX, AZ, IL

Selected trials by therapeutic area — complete trial list available upon request

### MASH / NASH / Hepatology

- ALT-801-301: Pemvidutide Phase 3 — Noncirrhotic MASH, Efficacy, Safety & Clinical Outcomes (Altimmune, 2026)
- Efruxifermin Phase 3 — Non-Cirrhotic & Compensated Cirrhosis NASH/MASH with Fibrosis (2023–2024)
- Survodutide Phase 3 — NASH/MASH with F2-F3 Stage Liver Fibrosis (2024)
- Lanifibranor Phase 3 — Non-Cirrhotic NASH, F2/F3 Fibrosis (2022)
- Pemvidutide Phase 2 — NASH & MASLD with Concomitant GLP-1 Receptor Agonist Therapy (2023)
- Semaglutide + Cilofexor/Firsocostat Phase 2 — Compensated NASH Cirrhosis (F4) (2023)
- Efinopegdutide (MK-6024) Phase 2b — Pre-Cirrhotic Nonalcoholic Steatohepatitis (2023)
- Cotadutide Phase 2b/3 — Non-Cirrhotic NASH with Fibrosis (2022)
- ASCEND-NASH Phase 2b — NASH with Advanced Liver Fibrosis (CRV431, 2022)

- AXA1125 EMMPACK Phase 2 — Non-Cirrhotic NASH with Fibrosis (2021)
- VK2809 VOYAGE Phase 2b — Non-Alcoholic Steatohepatitis, 52-week study (2021)
- GSK4532990 HORIZON Phase 2b / Phase 2a Extension — Pre-Cirrhotic NASH (2022–2024)

### Cardiometabolic, MACE & GLP-1 Endpoints

- COORDINATE-Diabetes — MACE Outcomes, Cardiovascular/Diabetes Care Coordination (Circulation 2024)
- TACT2 — MACE Prevention in Diabetic Post-MI Patients, Edetate Disodium Chelation (2016)
- THARROS Phase 3 — Cardiopulmonary Outcomes in COPD (2024)
- DIAMOND RCT — Patiromer for Hyperkalemia in Heart Failure (RAASi, 2019)
- CONNECT-HF — Care Optimization Clinical Trial for Heart Failure (2018)
- Zilebesiran RCT — Add-on Antihypertensive Therapy (2022)
- KBP-5074 Phase 3 — Mineralocorticoid Receptor Antagonist, Uncontrolled HTN with CKD 3b/4 (2021)

## SELECTED PUBLICATIONS & PRESENTATIONS

**Tannu M et al. (Weston P, contributing investigator).** Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease: Insights From COORDINATE-Diabetes. *Circulation*. 2024;150(3):180-189. [Impact Factor ~37]

**Vergis N, et al. (Weston P, author #8).** HSD17B13 expression in ballooned hepatocytes in steatotic liver disease; therapeutic targeting by GSK4532990 in ALD (STARLIGHT Phase II). *Poster #1495. AASLD The Liver Meeting*. November 2025; Washington, D.C. Funded by GSK.

Weston P, Alexander J, Patel M, et al. Hand-held echocardiography for ACS symptoms in the ED: 30-day outcome with normal LV wall motion. *Am Heart J*. 2004;148(6):1096-1101.

Floyd JS, Maynard C, Weston P, et al. Ischemic Preconditioning and Arterial Collateral Flow on ST Elevation and QRS Prolongation — Canine Acute Coronary Occlusion Model. *J Electrocardiol*. 2009;42(1):19-26.

## CREDENTIALS & EDUCATION

**MBA — Northwestern Kellogg School of Management** 2010 – 2012

**MD — University of Pittsburgh School of Medicine** 1998 – 2003

**Cardiovascular Fellowship — Boston University Medical Center** 2006 – 2009

**Residency, Internal Medicine — Duke University Medical Center** 2004 – 2006

**Internship, Internal Medicine — Duke University Medical Center** 2003 – 2004

**Clinical Research Fellow — Duke Clinical Research Institute** 2001 – 2002

**Board Certifications:** American Board of Internal Medicine (expires 12/2030) | American Board of Cardiovascular Diseases (recert. 2025)

## EXPERT NETWORK AFFILIATIONS

**GLG (Gerson Lehrman Group) | Guidepoint | AlphaSights | Third Bridge | Tegus | Expert Institute | Atheneum Partners | Inex One | Round Table Group**

*Full Academic & Regulatory CV | Complete Trial List (100+ studies) | Full Publications List — Available Upon Request*